Previous close | 6.09 |
Open | 5.99 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 5.96 - 6.03 |
52-week range | 2.85 - 14.55 |
Volume | |
Avg. volume | 104,717 |
Market cap | 73.303M |
Beta (5Y monthly) | -0.16 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.28 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 9.00 |
First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter Confirms Strategic Pivot Targeting the U.S. Consumer Healthcare Market Reaffirms 2024 Revenue Range of US$33 million to US$36 million LOS ANGELES, June 18, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced unaudited financial results for the first quarter ended March 31, 2024, along with recent business up
~ Emphasizes Strong Cash Position, No Debt, and A Dedicated Management Team Focused on Delivering Growth and Value to Shareholders ~LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, has engaged international investor relations specialists MZ Group ("MZ") to lead a comprehensive strategic investor relations and financial communications program across all key markets. MZ Group wil
Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2023, along with recent business updates.